Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-7535 tablets, a new oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1]. Company Summary - The subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. of Heng Rui Medicine is set to initiate clinical trials for HRS-7535 tablets shortly [1]. - HRS-7535 functions by activating GLP-1 receptors to promote insulin secretion from the pancreas, reduce glucagon secretion, and inhibit gastric emptying [1]. - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to a direct reduction in energy intake [1]. Industry Summary - The development of GLP-1 receptor agonists is significant in the treatment landscape for type 2 diabetes (T2DM) and obesity, addressing both metabolic control and weight management [1].

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] Group 1: Product Development - SHR-1826 is intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer that is c-Met overexpressing (2-3+, ≥50%) and has failed at least one line of systemic therapy [1]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.60%, ranking 8th among 31 primary industries, outperforming the CSI 300 index which rose by 2.18% [4][16] - The PE (TTM overall method, excluding negative values) for the pharmaceutical and biotechnology industry as of January 9, 2026, is 30.56x, up from 29.20x at the end of the previous period, indicating an upward valuation trend [4][21] - The top three sub-industries in terms of PE are vaccines (47.64x), hospitals (43.33x), and medical devices (39.44x), while pharmaceutical circulation has the lowest valuation at 15.42x [4][21] Industry Review - The report highlights significant developments in the pharmaceutical sector, including the release of the "Fourth Batch of Encouraged Generic Drug Catalog" aimed at optimizing the drug supply guarantee system and enhancing industry structure [6][26] - The report notes that 43 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 2.779 billion yuan, with 8 companies increasing holdings by 20 million yuan and 35 companies reducing holdings by 2.799 billion yuan [4] Important Industry News - The National Health Commission and other departments released the "Fourth Batch of Encouraged Generic Drug Catalog," which includes 21 varieties and 47 specifications, focusing on clinical needs and disease burdens [26][27] - The NMPA announced measures to strengthen the supervision and management of entrusted drug production, aiming to enhance drug quality assurance levels [29][30] - The NMPA also optimized the review and approval process for urgently needed overseas drugs, encouraging simultaneous global development and submission [31][32] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with strong pipeline differentiation, rapid clinical advancement, and robust overseas collaboration capabilities [7][8] - In the medical device sector, it recommends paying attention to companies with solid technical foundations and deep collaborations with leading hospitals and research institutions [8]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-7535 tablets, a new oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1]. Group 1: Product Development - The clinical trial approval for HRS-7535 tablets will allow the company to initiate trials in the near future [1]. - HRS-7535 functions by activating GLP-1 receptors, which promotes insulin secretion from the pancreas, reduces glucagon secretion, and inhibits gastric emptying [1]. - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1]. Group 2: Market Implications - The introduction of HRS-7535 could provide a new treatment option for type 2 diabetes (T2DM) patients, addressing both glycemic control and weight management [1].

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] Group 1: Product Development - SHR-1826 is intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer that is c-Met overexpressing (2-3+, ≥50%) and has failed at least one line of systemic therapy [1]

恒瑞医药公告称，子公司山东盛迪医药收到国家药监局关于HRS - 7535片的《药物临床试验批准通知 书》，将于近期开展临床试验。该药物拟用于高血压合并超重或肥胖治疗，是新型口服小分子胰高血糖 素样肽 - 1受体激动剂，全球尚无同类口服药上市。截至目前，相关项目累计研发投入约3.69亿元。药 品研发到上市周期长、环节多，存在不确定性，公司将推进项目并披露进展。 ...

Group 1 - The core point of the article is that Heng Rui Medicine's injectable SHR-1826 has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 2 - The announcement was made by Heng Rui Medicine, specifically through its subsidiary Suzhou Sediya Biopharmaceutical Co., Ltd [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] Company Summary - Heng Rui Medicine (600276.SH) announced the inclusion of its injectable SHR-1826 in the breakthrough therapy list by the NMPA [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 7.29 | 11.98% | 167.84万 | | 11.97亿 | | 000766 | 通化金马 | 27.87 | 9.98% | 46.86万 | | 12.97亿 | | 002940 | 昂利康 | 38.66 | 7.87% | 25.79万 | | 9.79亿 | | 300401 | 化园生物 | 17.36 | 5.60% | - 54.32万 | | 2666 | | 920367 | 新赣江 | 23.50 | 5.48% | 5.45万 | | 1.26亿 | | 688176 | 亚虹医药 | 12.60 | 5.09% | 19.90万 | | 2.45亿 | | 301281 | 科源制药 | 30.83 | 5.08% | 4.03万 | | 1.22亿 | | 000908 | *ST景峰 | 8.19 | 5.00% | 3.17万 | | 2599.61万 | ...

Group 1 - The core point of the article is that Hengrui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval for the environmental impact assessment of its Phase II construction project, with a total investment of 250 million yuan [1] - The "A-share Green Report" project aims to enhance the transparency of environmental information for listed companies, utilizing authoritative environmental regulatory data from 31 provinces and 337 cities [1] - The project includes monitoring the environmental performance of listed companies and their subsidiaries, providing professional data analysis and insights, and regularly updating the environmental risk rankings of these companies [1] Group 2 - The latest A-share Green Weekly Report (Issue No. 228) indicates that four listed companies have recently exposed environmental risks [1]